Purple Biotech (PPBT)
NASDAQ:PPBT
Want to see PPBT full AI Analyst Report?
Top Page
Purple Biotech
(NASDAQ:PPBT)
Select Model
Select Model
Rating:42Neutral
Price Target:
$4.50
▼(-7.60% Downside)
Action:ReiteratedDate:03/16/26
The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.
Positive Factors
Promising preclinical data (IM1240)
Robust preclinical activity across treatment‑resistant, PD‑1 and chemo‑resistant tumor samples supports the CAPTN‑3 platform’s translational potential. Durable efficacy signals and mechanistic data (NKG2A contribution, tertiary lymphoid structures) improve odds of clinical success and partner interest.
Negative Factors
Limited cash runway
With IND‑enabling toxicology and a planned Phase 1 start on the horizon, a runway into mid‑2027 is tight. The company will likely need financing or partnership before key clinical inflection points, creating execution risk and potential equity dilution that affects long‑term strategy.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising preclinical data (IM1240)
Robust preclinical activity across treatment‑resistant, PD‑1 and chemo‑resistant tumor samples supports the CAPTN‑3 platform’s translational potential. Durable efficacy signals and mechanistic data (NKG2A contribution, tertiary lymphoid structures) improve odds of clinical success and partner interest.
Read all positive factors
Purple Biotech (PPBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.25M
Dividend YieldN/A
Average Volume (3M)415.61K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS Growth34.49%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-19.85
Shares Outstanding929,240
10 Day Avg. Volume296,099
30 Day Avg. Volume415,608
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit32.61
Enterprise Value/Ebitda1.19
Forecast
1Y Price Target
$30.00Price Target Upside516.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-19.3
Revenue Forecast (FY)N/A
Purple Biotech Business Overview & Revenue Model
Company Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryo...
How the Company Makes Money
Purple Biotech’s business model is centered on monetizing its drug-development pipeline through a combination of (1) collaboration and licensing arrangements and (2) potential future product sales if any candidates receive regulatory approval. His...
Purple Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
43
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 195.80K | 0.00 | 0.00 |
| Gross Profit | -204.61K | -186.00K | -196.00 | -120.00 | -55.00 |
| EBITDA | -6.83M | -7.05M | -19.88M | -21.49M | -17.52M |
| Net Income | -26.81M | -7.24M | -19.88K | -21.67M | -18.38M |
Balance Sheet | |||||
| Total Assets | 17.57M | 37.04M | 44.30M | 54.62M | 70.20M |
| Cash, Cash Equivalents and Short-Term Investments | 9.57M | 8.52M | 15.41M | 32.11M | 47.20M |
| Total Debt | 244.00K | 183.00K | 351.00K | 515.00K | 749.00K |
| Total Liabilities | 7.91M | 4.13M | 10.01M | 7.52M | 5.09M |
| Stockholders Equity | 9.71M | 32.86M | 34.21M | 46.91M | 64.83M |
Cash Flow | |||||
| Free Cash Flow | -5.54M | -14.37M | -19.93M | -16.96M | -15.19M |
| Operating Cash Flow | -5.54M | -14.37M | -19.93M | -16.73M | -15.07M |
| Investing Cash Flow | 449.54K | 509.00K | 13.88M | 19.91M | 13.41M |
| Financing Cash Flow | 6.41M | 6.77M | 5.45M | 1.11M | 1.51M |
Purple Biotech Technical Analysis
Positive
4.87
Price Trends
4.60
Positive
5.86
Negative
9.84
Negative
Market Momentum
-0.06
Negative
62.15
Neutral
58.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Positive. The current price of 4.87 is above the 20-day moving average (MA) of 4.10, above the 50-day MA of 4.60, and below the 200-day MA of 9.84, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 62.15 is Neutral, neither overbought nor oversold. The STOCH value of 58.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Purple Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $6.25M | ― | -10.00% | ― | ― | 34.49% | |
| ― | $6.09M | -1.51 | -167.97% | ― | -44.44% | 23.15% | |
| ― | $2.62M | -0.17 | -168.95% | ― | ― | 83.36% | |
43 Neutral | $101.69M | 1.65 | -9999.00% | ― | ― | 62.19% |
* Healthcare Sector Average
PPBT
Purple Biotech
4.23
-19.77
-82.38%
TCRT
Alaunos Therapeutics
2.56
0.11
4.49%
OGEN
Oragenics
0.60
-4.97
-89.16%
PMCB
PharmaCyte Biotech
0.75
-0.49
-39.52%
KALA
KALA BIO
0.11
-3.86
-97.25%
Purple Biotech Corporate Events
Purple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform
Apr 27, 2026
On April 27, 2026, Purple Biotech reported new preclinical data for IM1240, the lead tri-specific antibody from its CAPTN-3 platform, showing potent anti-tumor activity in all seven tested treatment-resistant patient-derived tumor samples, includi...
Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform
Apr 23, 2026
On April 23, 2026, Purple Biotech announced it has established a Scientific Advisory Board made up of leading experts in T-cell and NK-cell biology, tumor immunology, and clinical oncology to guide development of its CAPTN-3 tri-specific antibody ...
Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
Mar 25, 2026
On March 25, 2026, Purple Biotech announced a collaboration with Boston-based Converge Bio to apply generative AI to the design and optimization of its next-generation tri-specific antibody platform for solid tumors. The partnership builds on prio...
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
Mar 19, 2026
Purple Biotech on March 18, 2026 reported that it has issued an updated March 2026 corporate presentation outlining progress across its immuno-oncology pipeline and platform. The company highlighted its CAPTN-3 conditionally activated tri-specific...
Purple Biotech Regains Nasdaq Compliance on Minimum Bid Price
Mar 17, 2026
On March 17, 2026, Purple Biotech announced it had regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company satisfied Nasdaq Listing Rule 5550(a)(2) after its American De...
Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform
Mar 13, 2026
On March 13, 2026, Israel-based Purple Biotech reported fourth-quarter and full-year 2025 results that underscored a strategic pivot toward its CAPTN-3 tri-specific antibody platform, advancing lead candidate IM1240 and naming IM1305 as a second d...
Purple Biotech to Implement ADS Ratio Change to Regain Nasdaq Bid-Price Compliance
Feb 25, 2026
On February 25, 2026, Purple Biotech announced it will change the ratio of its American Depositary Shares to ordinary shares from 1:200 to 1:2,000, effectively a one-for-ten reverse ADS split. The revised ADSs are expected to begin trading on or a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.